Novartis banks EC approval for Enerzair Breezhaler
The product includes the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
Read More
Tag: LABA
GSK, Innoviva’s Trelegy Ellipta cleared for COPD
GlaxoSmithKline and Innoviva have won European approval for the novel triple therapy inhaler Trelegy Ellipta, offering a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read More
GSK, Innoviva announce US nod for Trelegy Ellipta
GlaxoSmithKline and Innoviva have bagged a green light in the US for the novel triple therapy inhaler Trelegy Ellipta, opening the door to a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read More
EU nod for Chiesi’s COPD therapy
European regulators have green-lighted Chiesi’s new chronic obstructive pulmonary disease (COPD) maintenance therapy Trimbow.
Read More
GSK files for extended use of Relvar Ellipta in asthma
GlaxoSmithKline and Innoviva have applied to market Relvar Ellipta for extended use in patients with asthma who are already adequately controlled on inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy.
Read More
GSK files three-drug COPD inhaler in the US
GlaxoSmithKline and Innoviva have filed for approval in the US of a new once-daily, triple combination therapy for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), some 18 months earlier than originally planned.
Read More
Flutiform fails to hit targets in COPD trial
UK group Vectura saw its shares drop 10 percent after partner Munipharma reported that respiratory drug flutiform failed to hit targets in a late-stage trial involving patients with chronic obstructive pulmonary disease.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
